LRCX · Investment summary · as of 29 July 2026
Priced for an operating path the record does not support
Business type: Compounder · cyclical or commodity-sensitive
The operating path required by today's price is not achievable on the evidence.
At $269.51, LRCX requires a 40% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 16%.
The value rests on an exit multiple of 13.7x and a terminal operating margin of 31%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: the receivables build proving to be pulled-forward revenue.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Cyclical: revenue and margin driven by exogenous WFE/fab-utilisation/memory-price cycle. |
| What do we forecast? | Revenue growth of 16% demonstrated; a terminal operating margin of 31%; an exit multiple of 13.7x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -23.3 percentage points. |
| What is it worth? | Not determined — It is struck at this name's next touch. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 28 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Named cause: the receivables build proving to be pulled-forward revenue. DSO rose 12.9 days as receivables grew 58.1% against revenue of 30.0%. If that reverses — i.e. if Q4 FY2026's 15.1% sequential revenue jump was shipment timing rather than demand — the September-2026 and December-2026 quarters absorb the payback, and Lam re-rates on decelerating revenue while the memory narrative is still priced in. Combine the FY2024 trough operating margin (28.6%) with a 25% revenue decline to $17.4bn — both printed inside the last three years — and EBIT is ~$5.0bn, net income ~$4.2bn, EPS ~$3.38.
Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored
The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause: the receivables build proving to be pulled-forward revenue. |
| Momentum | Met | Does price action support or complicate entry timing? |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Met | Is the house-versus-Street disagreement identified and quantified? |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -23.3 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: the receivables build proving to be pulled-forward revenue. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $202.13, which forces an immediate review.